Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 5/20 | 0.47 |
| ▸ | HTR1A | P08908 | 10/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.36 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.34 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26646365 | 1.00 | PDE4A (0.47) | PDE4AHTR1ASLC6A4HTR2AHTR2C | |
| SCHEMBL26646337 | 0.79 | HTR1A (0.52) | HTR1ASLC6A4HTR2AHTR2CGRM4 | |
| SCHEMBL31316087 | 0.79 | HTR1A (0.52) | HTR1ASLC6A4HTR2AHTR2CGRM4 | |
| SCHEMBL31316098 | 0.79 | SLC6A4 (0.43) | HTR1ASLC6A4HTR2AHTR2CGRM4 | |
| SCHEMBL26646217 | 0.79 | SLC6A4 (0.43) | HTR1ASLC6A4HTR2AHTR2CGRM4 | |
| SCHEMBL26646074 | 0.77 | SLC6A4 (0.41) | HTR1ASLC6A4HTR2AHTR2CGRM4 | |
| SCHEMBL31316021 | 0.77 | SLC6A4 (0.41) | HTR1ASLC6A4HTR2AHTR2CGRM4 | |
| SCHEMBL30600597 | 0.76 | HTR2A (0.63) | HTR1ASLC6A4HTR2AHTR2CFFAR2 | |
| SCHEMBL31373456 | 0.75 | KCNH2 (0.50) | PDE4AHTR1ASLC6A4HTR2AHTR2C | |
| SCHEMBL26650637 | 0.75 | KCNH2 (0.50) | PDE4AHTR1ASLC6A4HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119156382-A | Kinesin KIF18A inhibitor and application thereof | 上海湃隆生物科技有限公司 | 2024-12-17 | — | — | CN | disclosed |